American Society of Hematology

Figure 4

$Figure 4. Resistance to apoptosis induced by soluble FasL can be overcome in patients with SzS. (A) Selected resistant patients expressing low levels (patients 7, 8, and 9) or no Fas (patient 6) were exposed to increasing doses of MFL. Viability was assessed 6 to 8 hours after MFL treatment by flow cytometry analysis of annexin-V/PI staining. One representative of 2 experiments. In the same way, Fas-expressing HUT78 and MyLa and Fas-negative SeAx cell lines were treated with MFL. (B) Two selected HD (1 and 2) and patients with SzS (1 and 2) were exposed to 100 IU/mL IFN-α (left panels) or IFN-γ (right panels) before treatment with 100 ng/mL FasL. Increase of the measured Fas-MFI (top panels) and increase of the annexin-V+/PI− apoptotic fraction (bottom panels) are reported.$

Resistance to apoptosis induced by soluble FasL can be overcome in patients with SzS. (A) Selected resistant patients expressing low levels (patients 7, 8, and 9) or no Fas (patient 6) were exposed to increasing doses of MFL. Viability was assessed 6 to 8 hours after MFL treatment by flow cytometry analysis of annexin-V/PI staining. One representative of 2 experiments. In the same way, Fas-expressing HUT78 and MyLa and Fas-negative SeAx cell lines were treated with MFL. (B) Two selected HD (1 and 2) and patients with SzS (1 and 2) were exposed to 100 IU/mL IFN-α (left panels) or IFN-γ (right panels) before treatment with 100 ng/mL FasL. Increase of the measured Fas-MFI (top panels) and increase of the annexin-V⁺/PI⁻ apoptotic fraction (bottom panels) are reported.

This Feature Is Available To Subscribers Only